Vaxcyte, Inc. — Director's Dealing 2023

Sep 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2023-09-05

Reporting Person: GUGGENHIME ANDREW (President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-05	Common Stock	F	3568	$51.00	Disposed	79474	Direct

Footnotes

F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.

F2: Includes 1,040 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2023.